Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$29.78 USD
-0.58 (-1.91%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $29.80 +0.02 (0.07%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Cassava Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 121 | 201 | 233 | 94 | 23 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 10 | 11 | 0 | 0 |
Total Current Assets | 130 | 211 | 244 | 94 | 23 |
Net Property & Equipment | 22 | 23 | 21 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 1 | 1 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 152 | 235 | 267 | 94 | 23 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 4 | 7 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 2 | 5 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Total Current Liabilities | 14 | 7 | 13 | 2 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14 | 7 | 13 | 2 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 518 | 511 | 461 | 267 | 191 |
Retained Earnings | -381 | -284 | -207 | -175 | -169 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 137 | 228 | 254 | 92 | 22 |
Total Liabilities & Shareholder's Equity | 152 | 235 | 267 | 94 | 23 |
Total Common Equity | 137 | 228 | 254 | 92 | 22 |
Shares Outstanding | 42.10 | 40.00 | 40.00 | 35.20 | 21.80 |
Book Value Per Share | 3.27 | 5.69 | 6.35 | 2.62 | 1.01 |
Fiscal Year End for Cassava Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 207 | 124 | 121 | 142 | 168 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 10 | 9 | 8 | 6 |
Total Current Assets | 222 | 134 | 130 | 150 | 175 |
Net Property & Equipment | 21 | 22 | 22 | 22 | 22 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 244 | 156 | 152 | 173 | 197 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 53 | 10 | 11 | 9 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 3 | 8 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 65 | 0 | 0 | 0 |
Total Current Liabilities | 55 | 77 | 14 | 17 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 55 | 77 | 14 | 17 | 18 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 539 | 434 | 518 | 515 | 514 |
Retained Earnings | -350 | -356 | -381 | -360 | -334 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 189 | 79 | 137 | 155 | 179 |
Total Liabilities & Shareholder's Equity | 244 | 156 | 152 | 173 | 197 |
Total Common Equity | 189 | 79 | 137 | 155 | 179 |
Shares Outstanding | 47.90 | 43.20 | 42.10 | 41.90 | 41.70 |
Book Value Per Share | 3.95 | 1.82 | 3.27 | 3.70 | 4.30 |